Holen Sie sich die Stockscreener-App
4.20
2.55%
-0.11
Handel nachbörslich:
4.10
-0.10
-2.38%
Schlusskurs vom Vortag:
$4.31
Offen:
$4.34
24-Stunden-Volumen:
209.30K
Relative Volume:
0.15
Marktkapitalisierung:
$28.91M
Einnahmen:
$5.21M
Nettoeinkommen (Verlust:
$-26.35M
KGV:
-0.1309
EPS:
-32.0862
Netto-Cashflow:
$-20.84M
1W Leistung:
-22.51%
1M Leistung:
-28.08%
6M Leistung:
+661.56%
1J Leistung:
+1,974%
1-Tages-Spanne:
$4.10
$4.3828
1-Wochen-Bereich:
$4.10
$5.46
52-Wochen-Spanne:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
4.20 | 28.91M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Lake Street | Buy |
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics Inc (PSTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Plus Therapeutics Inc (PSTV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Plus Therapeutics Inc (PSTV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Plus Therapeutics Inc (PSTV) Institutional Confidence - TradingKey
Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Plus Therapeutics Inc (PSTV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Plus Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
PSTV Should I Buy - Intellectia AI
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital - Moomoo
PSTV Maintained by Ascendiant Capital -- Price Target Lowered to $57.00 - GuruFocus
[EFFECT] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
PLUS THERAPEUTICS INC (PSTV) Stock Chart - ChartMill
Plus Therapeutics Launches New At-The-Market Equity Program - The Globe and Mail
PLUS THERAPEUTICS, INC. Files Form 8-K with SEC Detailing Material Definitive Agreement – June 2026 - Minichart
Plus Therapeutics Launches $17.35 Million ATM Equity Program With Canaccord Genuity - TradingView
Plus Therapeutics (NASDAQ: PSTV) sets $17,350,000 at-the-market stock program - Stock Titan
Plus Therapeutics (PSTV) adds Form of Indenture to S-3/A filing - Stock Titan
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform - Yahoo Finance
CNSide Diagnostics receives laboratory accreditation from CAP By Investing.com - Investing.com Nigeria
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory - The Manila Times
CNSide Diagnostics, a Plus Therapeutics Subsidiary, Achieves Prestigious CAP Accreditation for Clinical Laboratory - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) launches $17.35M ATM with Canaccord - Stock Titan
Plus TherapeuticsMay Offer And Sell Up To $100 Million Of Securities From Time To TimeSEC Filing - TradingView
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV stock on track for best week since September — here’s what is driving the rally - MSN
PLUS THERAPEUTICS (PSTV) Holds Near Support as Modest Gains PersistDefined Outcome ETF - thelegaladvocate.com
Plus Therapeutics (PSTV) Highlights Economic Benefits of Early D - GuruFocus
Plus Therapeutics Presents Health Economics Study Demonstrating Substantial Healthcare Cost Reduction with CNSide Diagnostic Platform - marketscreener.com
Plus Therapeutics study shows CNSide may cut LM costs by 40% - Investing.com Nigeria
Plus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual Meeting - Quiver Quantitative
Plus' CNSide Diagnostic Platform Demonstrates Substantial - GlobeNewswire
PSTV Technical Analysis | Trend, Signals & Chart Patterns | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $12 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Total equity of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net current asset value per share of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total common shares outstanding of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Total debt of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Net margin % of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics Stockholders Back Directors and Incentive Plan - TipRanks
Number of shareholders of Plus Therapeutics, Inc. – DUS:XMP1 - TradingView
Plus Therapeutics (PSTV) Forms Strategic Alliance with Ephemeral Technologies - GuruFocus
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics partners with Ephemeral on AI platform By Investing.com - Investing.com South Africa
Plus Therapeutics, Inc. Cash Flow – DUS:XMP1 - TradingView
Plus Therapeutics partners with Ephemeral on AI platform - Investing.com
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology - The Manila Times
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):